Ensysce Biosciences (ENSCW) Notes Payables (2019 - 2025)
Ensysce Biosciences (ENSCW) reported Notes Payables of $306708.0 for Q4 2025, up 1.67% year-over-year from $301660.0 in Q4 2024, and down 20.89% quarter-over-quarter from $387702.0 in Q3 2025.
Ensysce Biosciences (ENSCW) Notes Payables (2019 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 7 years of Notes Payables data on file, last reported at $306708.0 in Q4 2025.
- Notes Payables for Q4 2025 came in at $306708.0, up 1.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $306708.0 (up 1.67% YoY), and the FY2025 annual result was $306708.0, up 1.67% from the prior year.
- Notes Payables retreated to $306708.0 in Q4 2025 per ENSCW's latest filing, from $387702.0 in the prior quarter.
- Over five years, Notes Payables peaked at $12.7 million in Q4 2021 and troughed at $245973.0 in Q1 2024.
- A 5-year average of $2.7 million and a median of $450100.5 in 2023 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2022 and 2023: Notes Payables surged 1616.54% in 2022, then slumped 96.07% in 2023.
- A 5-year view of Notes Payables shows it stood at $12.7 million in 2021, then slumped by 65.43% to $4.4 million in 2022, then plunged by 80.6% to $854697.0 in 2023, then tumbled by 64.71% to $301660.0 in 2024, then advanced by 1.67% to $306708.0 in 2025.
- Business Quant data shows ENSCW's Notes Payables at $306708.0 in Q4 2025, $387702.0 in Q3 2025, and $424521.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 306,708.00 |
| Sep 30, 2025 | 387,702.00 |
| Jun 30, 2025 | 424,521.00 |
| Mar 31, 2025 | 257,383.00 |
| Dec 31, 2024 | 301,660.00 |
| Sep 30, 2024 | 387,176.00 |
| Jun 30, 2024 | 454,463.00 |
| Mar 31, 2024 | 245,973.00 |
| Dec 31, 2023 | 854,697.00 |
| Sep 30, 2023 | 350,932.00 |
| Jun 30, 2023 | 445,738.00 |
| Dec 31, 2022 | 4.41 Mn |
| Sep 30, 2022 | 8.94 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 6.07 Mn |
| Dec 31, 2021 | 12.75 Mn |
| Sep 30, 2021 | 2.80 Mn |
| Jun 30, 2021 | 466,055.00 |
| Dec 31, 2020 | 4.25 Mn |
| Mar 31, 2020 | 566,268.00 |